

Adjuvant/Curative/Neo-adjuvant Adrenal Cancer Regimens

The following table lists the evidence-informed regimens (both IV and non-IV) for adrenal cancer used in the adjuvant/curative/neo-adjuvant setting. It is expected that the prescribing oncologist will select the regimen from the list of evidence-informed regimens that is most appropriate for their patient taking account of a variety of disease-specific and patient-related factors.

Regimens highlighted in red contain an expensive drug that is not currently publicly funded for the regimen and treatment intent.

Adrenal Cancer	
Regimen Code	Regimen Abstract
MTTN	Mitotane 1 to 3 g PO Daily – Not currently publicly funded for this regimen and intent

Last Updated: November 2017